It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Central nervous system (CNS) infections cause substantial morbidity and mortality worldwide, with mounting concern about new and emerging neurologic infections. Stratifying etiologies based on initial clinical and laboratory data would facilitate etiology-based treatment rather than relying on empirical treatment. Here, we report the epidemiology and clinical outcomes of patients with CNS infections from a prospective surveillance study that took place between 2013 and 2016 in Singapore. Using multiple correspondence analysis and random forest, we analyzed the link between clinical presentation, laboratory results, outcome and etiology. Of 199 patients, etiology was identified as infectious in 110 (55.3%, 95%-CI 48.3–62.0), immune-mediated in 10 (5.0%, 95%-CI 2.8–9.0), and unknown in 79 patients (39.7%, 95%-CI 33.2–46.6). The initial presenting clinical features were associated with the prognosis at 2 weeks, while laboratory-related parameters were related to the etiology of CNS disease. The parameters measured were helpful to stratify etiologies in broad categories, but were not able to discriminate completely between all the etiologies. Our results suggest that while prognosis of CNS is clearly related to the initial clinical presentation, pinpointing etiology remains challenging. Bio-computational methods which identify patterns in complex datasets may help to supplement CNS infection diagnostic and prognostic decisions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Duke-NUS Medical School, Emerging Infectious Diseases Program, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); SingHealth/Duke-NUS, Viral Research and Experimental Medicine Center, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
2 Singapore-MIT Alliance in Research and Technology, Antimicrobial Resistance Interdisciplinary Research Group, Singapore, Singapore (GRID:grid.429485.6) (ISNI:0000 0004 0442 4521)
3 Singapore General Hospital, Department of Infectious Diseases, Singapore, Singapore (GRID:grid.163555.1) (ISNI:0000 0000 9486 5048)
4 National University Hospital, Department of Neurology, Singapore, Singapore (GRID:grid.412106.0) (ISNI:0000 0004 0621 9599)
5 Changi General Hospital, Department of General Medicine, Singapore, Singapore (GRID:grid.413815.a) (ISNI:0000 0004 0469 9373)
6 Khoo Teck Puat Hospital, Department of Medicine, Singapore, Singapore (GRID:grid.415203.1) (ISNI:0000 0004 0451 6370)
7 Tan Tock Seng Hospital, Infectious Diseases Department, Singapore, Singapore (GRID:grid.240988.f)
8 University of Oxford, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
9 Duke-NUS Medical School, Emerging Infectious Diseases Program, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); National University of Singapore, Saw Swee Hock School of Public Health, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); National University of Singapore, Department of Pharmacy, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
10 Duke-NUS Medical School, Emerging Infectious Diseases Program, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); Singapore General Hospital, Department of Infectious Diseases, Singapore, Singapore (GRID:grid.163555.1) (ISNI:0000 0000 9486 5048)
11 Duke-NUS Medical School, Emerging Infectious Diseases Program, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); SingHealth/Duke-NUS, Viral Research and Experimental Medicine Center, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); Singapore-MIT Alliance in Research and Technology, Antimicrobial Resistance Interdisciplinary Research Group, Singapore, Singapore (GRID:grid.429485.6) (ISNI:0000 0004 0442 4521); National University of Singapore, Saw Swee Hock School of Public Health, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); National University of Singapore, Department of Microbiology and Immunology, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
12 Duke-NUS Medical School, Emerging Infectious Diseases Program, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924)
13 National Neuroscience Institute, Department of Neurology, Singapore, Singapore (GRID:grid.276809.2) (ISNI:0000 0004 0636 696X)